Supporting information

Recognition of acrolein-specific epitopes by B cell receptors triggers an innate immune response

Ryunosuke Endo¹, Kazuki Uchiyama¹, Sei-Young Lim¹, Masanori Itakura¹, Takahiro Adachi², and Koji Uchida^{1, 3, 4}

Table of Contents

- Figure S1. Sorting of B cell subsets.
- Figure S2. Representative flow-cytometry plots of the PerC B cells treated with biotin-BSA or biotin-acrBSA.
- Figure S3. Representative flow-cytometry plots of PerC B-1a cells treated with biotin-BSA or biotin-acrBSA.
- Figure S4. DNA and amino acid sequences of VH in IgM mAb RE-G25.
- Figure S5. DNA and amino acid sequences of VL in IgM mAb RE-G25.
- Figure S6. Sorting of acrolein-binding (ACR⁺) and acrolein-non-binding (ACR⁻) B cell populations from the PerC of BALB/c mice.




Figure S1. Sorting of B cell subsets.

B cell populations were defined as the total B cells (CD19⁺), B-2 cells (CD19⁺CD5⁻CD23⁺), B-1a cells (CD19⁺CD5⁺), and B-1b cells (CD19⁺CD5⁻CD23⁻).




Figure S2. Representative flow-cytometry plots of the PerC B cells treated with biotin-BSA or biotin-acrBSA.

The PerC cells that had been treated with biotin-BSA (*upper three panels*) or biotin-acrBSA (*lower three panels*) for 72 h were sorted into the B cell subsets (B-1a, B-1b, and B-2 cells) and the changes in the number of plasma cells were measured. The gated B cell populations were stained for CD19 (anti-mouse CD19-APC) versus CD138 (anti-mouse CD138-FITC-PECy7).




Figure S3. Representative flow-cytometry plots of PerC B-1a cells treated with biotin-BSA or biotin-acrBSA.

The PerC cells treated with biotin-BSA (*left*) or biotin-acrBSA (*right*) for 72 h were sorted into the B-1a cells and the changes in the number of antigen-binding cells were measured. The gated B-1a cell populations were stained for CD19 (anti-mouse CD19-APC) versus biotin (anti-mouse SA-PECy7).

VH: base sequence

GAGGTGCAGCTGGTGGAGTCTGGGGGAGACTTAGTGAAGCCTGGAGGGTC
CCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTATGGCA
TGTCTTGGGTTCGCCAGACTCCAGACAAGAGGCTGGAGTGGGTCGCAACC
ATTAGTAGTGGTGGTAGTTACACCTACTATCCAGACAGTGTGAAGGGGCG
ATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGA
GCAGTCTGAAGTCTGAGGACACACCCATGTATTACTGTGCAAGACATGAT
TACGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAG

VH: amino acid sequence

CDR1

EVQLVESGGDLVKPGGSLKLSCAAS GFTFSSYGMSWVRQTPDKRLEWVAT
CDR2

CDR3

ISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHD

YDYWGQGTTLTVSS

Figure S4. DNA and amino acid sequences of VH in IgM mAb RE-G25. The CDRs are highlighted.

VL: base sequence

VL: amino acid sequence

CDR1

CDR2

D | QMNQSPSSLSASLGDT | T | T CHA SQN | N VWL SWYQQKPGN | PKLL | Y K

CDR3

ASNLHTGVPSRFSGSGSGTGFTLT | SSLQPED | ATYY CQQGQSYPLT FGA

GTKLE | K

Figure S5. DNA and amino acid sequences of VL in IgM mAb RE-G25. The CDRs are highlighted.




Figure S6. Sorting of acrolein-binding (ACR $^+$) and acrolein-non-binding (ACR $^-$) B cell populations from the PerC of BALB/c mice.